Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

DHG Pharmaceutical JSC (HoSE: DHG), one of the leading pharmaceutical firms in Vietnam, reported audited net profit of VND852 billion ($32.35 million) in 2025, down 5% from its pre-audit figure, as additional tax obligations and provisions weighed on earnings.

After audit adjustments, net profit still rose 9.4% compared to 2024’s VND779 billion ($29.58 million), reflecting steady demand in Vietnam’s pharmaceutical market despite rising regulatory and compliance costs.

According to the audited financial statements, the company recorded net revenue of VND5.27 trillion ($199.97 million), unchanged from earlier disclosures, while gross profit reached VND2.51 trillion ($95.14 million), down slightly by VND6 billion ($227,800).

Despite the downward adjustment, the firm exceeded the year’s profit target by 5%, underscoring resilient operating performance.

The audit highlighted the impact of the parliament’s Resolution 107/2023/QH15, which introduces a 15% global minimum corporate tax rate for large multinational-backed firms.

With Japan’s Taisho Pharmaceutical holding a controlling 51.01% stake, DHG had previously benefited from preferential tax rates below the 15% threshold. This triggered additional tax liabilities under the new mechanism.

As a result, the company booked VND33.01 billion ($1.25 million) in additional corporate tax for 2025, VND21.98 billion ($834,500) in back payments for 2024, and VND1.4 billion ($53,150) paid on behalf of Taisho Vietnam.

Beyond tax adjustments, DHG increased provisions related to environmental obligations. The company set aside an additional VND38.1 billion ($1.45 million) for site restoration and cleanup, bringing total long-term provisions for this purpose to VND81.46 billion ($3.09 million) by end-2025. It also recorded VND4 billion ($151,870) in short-term expenses tied to recycling and packaging treatment.

Separately, total revenue from sales and services surpassed VND6 trillion ($222.8 million) for the first time, reaching VND6.14 trillion ($233 million), up more than 7% year-on-year.

DHG shares ended up 0.3% to VND100,100 ($3.8) each on Tuesday.

  • Related Posts

    Star Bio Pharma Global strengthens its position in the global nutraceutical supply Chain

    Star Bio Pharma Global Pvt. Ltd., a rapidly growing pharmaceutical and nutraceutical ingredients manufacturer, has further strengthened its position in India’s specialty ingredients sector by emerging as the country’s leading…

    Chemists demand fair competition in pharma market amid online sales concerns

    The All India Organisation of Chemists and Druggists (AIOCD) demanded that the government ensure an equitable ecosystem for all the players to sustain in the market by ensuring a level…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Star Bio Pharma Global strengthens its position in the global nutraceutical supply Chain

    Star Bio Pharma Global strengthens its position in the global nutraceutical supply Chain

    Chemists demand fair competition in pharma market amid online sales concerns

    Chemists demand fair competition in pharma market amid online sales concerns

    DCA busts unlicensed shop, seizes meds worth Rs 18000

    DCA busts unlicensed shop, seizes meds worth Rs 18000

    Health ministry concludes national review meeting on disease surveillance and public health programmes

    Health ministry concludes national review meeting on disease surveillance and public health programmes

    Five Women Critical After C-Section Delivery At Jodhpur’s Umaid Hospital

    Five Women Critical After C-Section Delivery At Jodhpur’s Umaid Hospital

    Gates MRI and Serum Institute of India Sign Landmark Agreement to Manufacture M72/AS01E Tuberculosis Vaccine Candidate

    Gates MRI and Serum Institute of India Sign Landmark Agreement to Manufacture M72/AS01E Tuberculosis Vaccine Candidate